VolitionRx (NYSE:VNRX) had its price target lowered by analysts at D. Boral Capital from $5.00 to $3.00. They now have a "buy" rating on the stock.
Volition Issues Business Review 2025
Volition Solves Liquid Biopsy's "Needle in a Haystack" Problem; Achieves 180-fold (18,000%) Enrichment
Volition Announces Two Abstracts were Presented at the North America Conference on Lung Cancer
VolitionRx (NYSE:VNRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.